紫光控股(00365.HK):要約人完成收購公司股份持股達67.82%
格隆匯9月26日丨紫光控股(00365.HK)及要約人公佈,所有條件均已按照股份購買協議達成,並已於2019年9月26日完成。根據股份購買協議的條款,合共9.87億股股份已由賣方轉讓予芯鼎,對價為港幣9.9億元。
於完成後,聯合要約人及其一致行動人士(包括上海半導體裝備材料基金及河南戰興基金)將於9.87億股股份中擁有權益,相當於本公司已發行股本總額約67.82%。因此,根據收購守則,聯合要約人須就所有已發行股份作出強制性無條件現金要約。作為聯合要約人的代表,中金公司將遵守收購守則,根據收購守則發出綜合文件及依照其中所載的條款作出要約。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.